Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsBusiness Wire • 10/02/23
Dividend Growth Predictions For 15 Companies Announcing Annual Boosts In OctoberSeeking Alpha • 10/02/23
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple MyelomaPRNewsWire • 09/29/23
Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 YearsThe Motley Fool • 09/29/23
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell LymphomaPRNewsWire • 09/25/23
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementBusiness Wire • 09/22/23
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma ProminencePRNewsWire • 09/18/23
AbbVie Inc. (ABBV) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)Seeking Alpha • 09/13/23
AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"PRNewsWire • 09/13/23